Following quite encouraging news from the laboratory on Monday, Amgen (AMGN 4.07%) was something of a stock market favorite the following day. Its shares closed the trading session more than 4% higher on the back of both that sentiment and a pair of optimistic analyst takes on the latest development. With that share price rise, Amgen easily beat the S&P 500 index, which slid by 0.1%.Cancer drug does well in testingThat news concerned Amgen's investigational stomach cancer drug, bemarituzumab. The company an ...